Trial Profile
A randomized controlled trial of sequential peginterferon-alpha and telbivudine or vice versa for 48 weeks in HBeAg-negative chronic hepatitis B
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2012
Price :
$35
*
At a glance
- Drugs Peginterferon alfa (Primary) ; Telbivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 01 Sep 2012 New trial record